Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Carboplatin And Liposomal Doxorubicin For Ovarian Cancer

J. Nguyen, D. Solimando, J. Waddell
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
This paper references
10.1200/JCO.2012.30.15_SUPPL.E13027
Impact of weight and creatinine measurements in carboplatin dosing.
Feriel Boumedien (2012)
10.1006/GYNO.1993.1184
Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
T. Cornelison (1993)
10.1200/JCO.2010.33.8566
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
S. Pignata (2011)
10.1054/bjoc.2001.2045
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy
R. de Wit (2001)
10.1093/AJHP/44.1.124
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Y. Cheung (1987)
10.1016/j.ejca.2014.11.017
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
S. Mahner (2015)
10.1016/J.YGYNO.2007.08.075
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
D. Alberts (2008)
10.1093/ANNONC/MDL376
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.
J. Ferrero (2007)
10.1200/JCO.2002.02.026
Revision of the American Joint Committee on Cancer staging system for breast cancer.
S. Singletary (2002)
New guidelines for carboplatin dosing
R. O’Cearbhaill (2012)
10.1186/1741-7015-8-3
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
D. Bafaloukos (2010)
10.2165/00003495-197917020-00002
Drug Prescribing in Renal Failure
W. Bennett (2012)
10.1016/j.ygyno.2008.09.033
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
S. Hsiao (2009)
10.1016/j.lungcan.2012.10.009
Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
Dieter Kaag (2013)
10.1016/j.jaci.2009.02.042
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
P. Hesterberg (2009)
10.1159/000227637
The severity and pattern of emesis following different cytotoxic agents.
M. Martín (1996)
10.1200/JCO.2009.25.7519
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
É. Pujade-Lauraine (2010)
10.2174/138161208786369803
Hypersensitivity to antineoplastic agents.
M. Castells (2008)
10.1007/BF00417477
A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin
M. Soukop (2004)
10.1200/jco.2007.25.18_suppl.15504
Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard
R. Cathomas (2007)
patients with low serum creatinine concentrations using CKDEPI and Cockcroft - Gault with different weight descriptors
R O’Cearbhaill (2013)
10.1200/JCO.2005.04.022
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.
O. Geling (2005)
10.1111/IGC.0b013e3181a8b938
Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer
B. Rapoport (2009)
10.1200/JCO.2006.06.4451
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
T. Smith (2006)
10.1177/1078155214546016
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags
A. Myers (2016)
10.1007/s00280-008-0856-x
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
C. Ekhart (2008)
10.1177/106002807400801104
Clinical Pharmacy: Case Studies
M. Mccarron (1974)
10.1007/s00280-005-0012-9
Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia
J. Herrington (2005)
patients with low serum creatinine concentrations using CKDEPI and Cockcroft - Gault with different weight descriptors
R O’Cearbhaill (2013)
10.6004/JNCCN.2009.0056
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
P. Engstrom (2009)
10.1093/annonc/mdr441
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
L. Gladieff (2012)
10.1200/JCO.1989.7.11.1748
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A. Calvert (1989)
10.1016/j.ygyno.2009.04.037
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
P. Power (2009)
and Drug Administration
US Foo (2014)
10.1016/S0084-3873(12)00200-3
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
J. Thigpen (2012)
Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
B. Weber (2009)
10.1016/0305-7372(95)90010-1
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
P. Kintzel (1995)
and Drug Administration
US Foo (2014)
10.1016/j.ygyno.2009.11.026
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
M. Markman (2010)
10.1093/jjco/hyv016
A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
T. Nakanishi (2015)
10.1159/000178760
Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial
S. Pignata (2008)
10.1200/JCO.2006.06.9591
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
M. Kris (2006)
10.1200/JOP.2015.009282
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
P. Hesketh (2016)
10.1200/JCO.1999.17.4.1141
Clinical features of hypersensitivity reactions to carboplatin.
M. Markman (1999)
Guidelines in Oncology-Myeloid Growth Factors
NCCN Clinical Practic (2015)
10.1007/BF01208844
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy
I. Smith (2005)
10.1097/00001813-199806000-00002
Use of granisetron in patients refractory to previous treatment with antiemetics.
J. Carmichael (1998)
The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy
JP Terrey (1996)
NCCN Clinical Practice Guidelines - Antiemesis . V . 2 . 2015 . National Comprehensive Cancer Network Web site
MG Kris (2016)
update of recommendations for the use of white blood cell growth factors : An evidence - based clinical practice guideline
PE Kintzel (2013)
10.1016/J.YGYNO.2007.08.008
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
A. Du Bois (2007)
10.2165/00003495-199700544-00007
Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer
D. Alberts (2012)
Gentamycin therapy
BJ Devine (1974)
10.1159/000227640
Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis.
A. Du Bois (1996)
10.1159/000180580
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft Dw (1976)
10.1093/annonc/mdr001
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
J. Kurtz (2011)
10.1016/J.YGYNO.2005.06.028
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
C. Lee (2005)
10.1016/S0169-5002(07)70339-2
13 Carboplatin dose calculation in lung cancer
M. Wheater (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar